DOC

Healthpeak is a healthcare REIT spanning lab/life-science, outpatient medical, and senior-housing properties, and its GAAP earnings are the wrong lens here. Net income fell 70.7% to $71.3M (EPS $0.10, an optically absurd 195.6x P/E), but the decline is driven largely by a $174M equity loss from unconsolidated joint ventures and higher D&A ($1.06B) and interest expense ($305M) — non-cash and capital-structure items typical of a REIT. The cash-generation picture is far healthier: operating cash flow rose 17.0% to $1.25B, comfortably covering the $849M of dividends paid (up 6.8%), with $467M of cash on hand (up 290%).

The operating fundamentals are mixed-to-constructive. Same-store adjusted NOI in senior housing grew 17.7% on higher occupancy (84.3% vs 82.6%) and rate increases, and total revenue (resident fees and services) is rising. But the lab/life-science segment faces real headwinds the 10-K spells out plainly: NIH grant-funding cuts, drug-pricing policy changes, visa restrictions on the scientific workforce, and competition from China-based biotech are pressuring life-science tenants' ability to fund R&D and pay/expand rent. The pending Janus Living senior-housing offering adds structural complexity.